BIIB059   Click here for help

GtoPdb Ligand ID: 11122

Immunopharmacology Ligand
Compound class: Antibody
Comment: BIIB059 is a fully humanized IgG1, clinical stage CLEC4C (BDCA2) targeting monoclonal antibody. It is being evaluated for ability to reduce release of disease-driving interferons (principally IFN-α) in SLE. BIIB059 was developed by Biogen, based on prior evidence of target engagement and SLE-applicable immunomodulatory efficacy of a humanized mAb against BDCA2 named 24F4A [2].
No information available.
Summary of Clinical Use Click here for help
BIIB059 has progressed to Phase 2 clinical evaluation as a monotherapy in patients with SLE and active CLE.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02847598 Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Phase 2 Interventional Biogen
NCT03224793 Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects. Phase 1 Interventional Biogen
NCT02106897 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus Phase 1 Interventional Biogen This study is known as the 'LILAC' trial. Results suggest that targeting pDCs has efficacy in patients with SLE, especially in patients with cutaneous manifestations for whom it reduced skin lesions. 1